IDENTIFICATION AND USE: Perflexane is a liquid. It is used in the electronics industry as a coolant and test bath medium. Non-toxic, non-ozone-depleting, inert reaction medium. It is also used as diagnostic aid (Ultrasound contrast agent). HUMAN EXPOSURE AND TOXICITY: There is no data. ANIMAL STUDIES: In dogs with preexisting pulmonary hypertension, perflexane lipid microspheres (16 mg/kg dose) increased both pulmonary artery pressure (PAP) transiently by an average of 5.7 mmHg (p < 0.05) 2 to 3 min after injection and pulmonary vascular resistance (PVR) by 5.9 mmHg per L/min (p < 0.05) 4 min after injection before returning to preinjection levels.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
毒性数据
大鼠急性经口毒性：> 40000 ppm/6小时
LC (rat) > 40,000 ppm/6h
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand-valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Halogenated aliphatic hydrocarbons and related compounds/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool. Administer activated charcoal ... . Cover skin burns with sterile dressings after decontamination ... . /Halogenated aliphatic hydrocarbons and related compounds/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag-valve-mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Consider vasosupressors if patient is hypotensive with a normal fluid volume. Watch for signs of cardiac irritability and fluid overload ... . Treat seizures with diazepam (Valium) or lorazepam (Ativan) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Halogenated aliphatic hydrocarbons and related compounds/
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
1,1-二氯-2,2,2-三氟乙烷（HCFC-123）、2-氯-1,1,1,2-四氟乙烷（HCFC-124）、1-氯-1,1-二氟乙烷（HCFC-142b）和全氟己烷（PFH）在大鼠中的代谢和药物动力学特性进行了研究。该研究是调查可能的健康危害计划的一部分，这些危害由作为灭火剂使用的候选卤素替代品所呈现。雄性Fischer-344大鼠和Sprague-Dawley大鼠仅通过鼻子暴露于10,000 parts per million (ppm)的HCFC-123、HCFC-124、HCFC-142b或PFH中2小时。收集24小时的尿液样本。在大鼠暴露后0小时或24小时处死，并通过气相色谱和氟-19核磁共振光谱法确定化合物及其代谢物在组织中的分布。HCFC-123、HCFC-124、HCFC-142b和PFH在暴露后立即处死的大鼠的所有组织中都被检测到。...在暴露后24小时检查的大鼠中，大多数卤代烃和代谢物的组织浓度低于检测限。...在尿液中没有检测到PFH的代谢物。...
The metabolism and pharmacokinetic characteristics of 1,1-dichloro-2,2,2-trifluoroethane (HCFC-123), 2-chloro-1,1,1,2-tetrafluoroethane (HCFC-124), 1-chloro-1,1-difluoroethane (HCFC-142b), and perfluorohexane (PFH) were studied in rats. The study was part of a program to investigate possible health hazards presented by candidate Halon replacements for use as a fire extinguishant. Male Fischer-344-rats and Sprague-Dawley-rats were exposed nose only to 10,000 parts per million (ppm) HCFC-123, HCFC-124, HCFC-142b, or PFH for 2 hours. Urine samples were collected for 24 hours. The rats were killed 0 or 24 hours after exposure and the tissue distribution of the compounds and their metabolites was determined by gas chromatography and fluorine-19 nuclear magnetic resonance spectroscopy. HCFC-123, HCFC-124, HCFC-142b, and PFH were detected in all tissues of rats killed immediately after exposure. ... Most tissue concentrations of the halocarbons and metabolites were below the detection limit in rats examined 24 hours post exposure. ... No PFH metabolites were detected /in urine/. ...
Provided is a method for producing a perfluoroalkylated compound at low cost, safely and with high efficiency. A method for producing a perfluoroalkylated compound, comprising reacting a bis(perfluoroalkanoyl) peroxide with a compound having a carbon-carbon unsaturated bond and/or an aromatic ring having a hydrogen atom bonded thereto in the presence of a copper catalyst.
[EN] METHODS FOR PRODUCING ARYLSULFUR PENTAFLUORIDES<br/>[FR] PROCÉDÉS DE PRODUCTION DE PENTAFLUORURES DE SOUFRE ARYLÉS
申请人：IM & T RES INC
公开号：WO2010014665A1
公开（公告）日：2010-02-04
Novel methods for preparing arylsulfur pentafluorides are disclosed. Arylsulfur halotetrafluoride is reacted with a fluoride source under hydrous conditions to form an arylsulfur pentafluoride. The purification method is also disclosed.
CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
申请人：Alnylam Pharmaceuticals, Inc.
公开号：US20160051691A1
公开（公告）日：2016-02-25
The present invention provides iRNA agents comprising at least one subunit of the formula (I):
wherein:
A and B are each independently for each occurrence O, N(R
N
) or S;
X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R;
R is L
G
, -Linker-L
G
, or has the structure shown below:
L
G
is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide;
R
N
is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and
Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.
[EN] TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS<br/>[FR] ADMINISTRATION CIBLÉE D'UN MÉDICAMENT FAISANT APPEL À DES COUPLEURS FONDÉS SUR L'AFFINITÉ
申请人：INVICTUS ONCOLOGY PVT LTD
公开号：WO2015148126A1
公开（公告）日：2015-10-01
The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.
[EN] IMMUNOPHILIN BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS DE LIAISON À L'IMMUNOPHILINE ET LEURS UTILISATIONS
申请人：UNIV CALIFORNIA
公开号：WO2020163594A1
公开（公告）日：2020-08-13
Described herein, inter alia, are immunophilin binding compounds and methods of treating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.
